BR0206986A - Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago - Google Patents
Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófagoInfo
- Publication number
- BR0206986A BR0206986A BR0206986-5A BR0206986A BR0206986A BR 0206986 A BR0206986 A BR 0206986A BR 0206986 A BR0206986 A BR 0206986A BR 0206986 A BR0206986 A BR 0206986A
- Authority
- BR
- Brazil
- Prior art keywords
- mif
- tumor
- methods
- treated
- macrophage migration
- Prior art date
Links
- 230000033228 biological regulation Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 title abstract 2
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 title abstract 2
- 230000007402 cytotoxic response Effects 0.000 title abstract 2
- 210000004698 lymphocyte Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 241000699670 Mus sp. Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000005012 migration Effects 0.000 abstract 2
- 238000013508 migration Methods 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 210000004988 splenocyte Anatomy 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"MéTODOS E COMPOSIçõES PARA MODULAR A REGULAçãO DA RESPOSTA CITOTóXICA DO LINFóCITO POR FATOR INIBITóRIO DE MIGRAçãO DE MACRóFAGO". é descrita a regulação da expressão da atividade de CTL através de fator inibitório de migração de macrófago (MIF). Em um modelo de camundongo empregando o tumor EL4, esplenócitos cultivados a partir de camundongos com tumor iniciado secretam níveis elevados de MIF seguindo estimulação de antígeno in vitro. Esplenócitos paralelos tratados com mAb anti-MIF de neutralização mostraram um aumento significante na resposta CTL contra células de tumor comparadas às culturas de controle tratadas com mAb, com expressão elevada de IFN<sym>. A histologia de tumores a partir de animais tratados com anti-MIF mostrou aumentos na infiltração de ambas as células T CD4¬ +¬ e CD8¬ +¬, bem como células de tumor apoptótico, consistente com a argumentação observada de atividade CTL in vivo por anti-MIF, a qual estava associada com expressão intensificada da cadeias <sym>~ c~ comuns do receptor IL-2 que medeia célula T CD8¬ +¬ sobreviventes. Células CD8¬ +¬ de camundongos contendo tumor tratado com anti-MIF mostraram migração aumentada para tumores de camundongos de controle. Métodos para aumentar um resposta CTL através de inibição de MIF são descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26091401P | 2001-01-12 | 2001-01-12 | |
PCT/US2002/000536 WO2002067862A2 (en) | 2001-01-12 | 2002-01-14 | Regulation of the ctl response by macrophage migration inhibitory factor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0206986A true BR0206986A (pt) | 2005-11-01 |
Family
ID=22991181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0206986-5A BR0206986A (pt) | 2001-01-12 | 2002-01-14 | Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago |
Country Status (8)
Country | Link |
---|---|
US (1) | US20020114812A1 (pt) |
EP (1) | EP1465660A4 (pt) |
JP (1) | JP2004531237A (pt) |
CN (1) | CN1842346A (pt) |
BR (1) | BR0206986A (pt) |
CA (1) | CA2434671A1 (pt) |
MX (1) | MXPA03006275A (pt) |
WO (1) | WO2002067862A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
EP1745194A4 (en) * | 2004-02-25 | 2008-02-06 | Us Dept Veterans Affairs | METHODS FOR DIAGNOSING AND TREATING CANCER OF BLADDER |
US20060229314A1 (en) | 2005-03-24 | 2006-10-12 | Jagadish Sircar | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
CA2717071A1 (en) * | 2008-03-20 | 2009-09-24 | Carolus Therapeutics, Inc. | Methods of treatment using anti-mif antibodies |
CA2716628A1 (en) * | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
NZ723731A (en) * | 2011-04-08 | 2020-05-29 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
EP3277718B1 (en) * | 2015-03-31 | 2021-03-24 | Baxalta GmbH | Dosage regimen for anti-mif antibodies |
CN105087610A (zh) * | 2015-09-11 | 2015-11-25 | 中国科学院海洋研究所 | 文蛤巨噬细胞迁移抑制因子基因及其编码蛋白和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
US6774227B1 (en) * | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
CA2389229A1 (en) * | 1999-10-29 | 2001-05-10 | The Picower Institute For Medical Research | Compounds having mif antagonist activity |
-
2002
- 2002-01-14 CN CNA028050800A patent/CN1842346A/zh active Pending
- 2002-01-14 BR BR0206986-5A patent/BR0206986A/pt not_active IP Right Cessation
- 2002-01-14 US US10/043,322 patent/US20020114812A1/en not_active Abandoned
- 2002-01-14 MX MXPA03006275A patent/MXPA03006275A/es unknown
- 2002-01-14 WO PCT/US2002/000536 patent/WO2002067862A2/en not_active Application Discontinuation
- 2002-01-14 CA CA002434671A patent/CA2434671A1/en not_active Abandoned
- 2002-01-14 EP EP02723045A patent/EP1465660A4/en not_active Withdrawn
- 2002-01-14 JP JP2002567234A patent/JP2004531237A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20020114812A1 (en) | 2002-08-22 |
EP1465660A2 (en) | 2004-10-13 |
EP1465660A4 (en) | 2005-09-21 |
MXPA03006275A (es) | 2005-09-08 |
JP2004531237A (ja) | 2004-10-14 |
CA2434671A1 (en) | 2002-09-06 |
WO2002067862A3 (en) | 2004-05-21 |
CN1842346A (zh) | 2006-10-04 |
WO2002067862A2 (en) | 2002-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2434640C2 (ru) | Лечение метастатического рака молочной железы | |
Dudley et al. | Adoptive-cell-transfer therapy for the treatment of patients with cancer | |
Tsung et al. | Lessons from Coley's toxin | |
BR0206986A (pt) | Métodos e composições para modular a regulação da resposta a citotóxica do linfócito por fator inibitório de migração de macrófago | |
DK1549353T3 (da) | Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer | |
ECSP055739A (es) | Anticuerpos de neutralización contra gdf-8, y sus usos | |
BR0208675A (pt) | Combinação imunoterapêutica para a imunoterapaia de tumores que superexpressam gangliosìdeos, uso da mesma e método para controlar o crescimento e/ou a proliferação de células tumorais que superexpressam gangliosìdeos | |
PL405074A1 (pl) | Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów trójglicerydów | |
DK0777499T3 (da) | Levende vaccine til behandling af tumorsygdomme | |
ATE287958T1 (de) | Verbesserte krebstherapie | |
MX2020009150A (es) | Anfifilos de cpg y usos de los mismos. | |
ATE512668T1 (de) | Allogenes tumortherapeutikum | |
AR052152A1 (es) | Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno | |
BRPI0417762A (pt) | organismo vivo, um plasmodium, método para inocular um hospedeiro vertebrado contra malária, composição de vacina, uso de um organismo vivo, um plasmodium, e, método de produção de uma composição de vacina | |
BR0211400A (pt) | Tratamento de distrofia muscular com células de sangue do cordão | |
Nikkhah | Nature as an ideal rhythm model for optimal cardiovascular physiology and health | |
EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
BR0308810A (pt) | Células hospedeiras tendo propriedades melhoradas de sobrevivência celular e métodos para gerar tais células | |
Watanabe et al. | Inhibitory effect of trehalose dimycolate (TDM) and its stereoisometric derivatives, trehalose dicorynomycolates (TDCMs), with low toxicity on lung metastasis of tumour cells in mice | |
WO2003104397A3 (en) | ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION | |
BR9915330A (pt) | Método para imunizar uma ave contra uma doença | |
GEP19991604B (en) | Human Follicle Stimulating Hormone Receptor | |
MXPA02009781A (es) | Isoformas de esfingosina cinasa tipo 2 de mamifero, clonacion, expresion y metodos de uso de las mismas. | |
Mbofung et al. | Off-the-shelf, iPSC-derived CAR-NK cells multiplexed-engineered for the avoidance of allogeneic host immune cell rejection | |
Rodado et al. | TAMI-53. Cysteine IS a limiting factor for glioma proliferation and survival |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2025 DE 27/10/2009. |